8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

____________________

Date of report (Date of earliest event reported): March 30, 2007

Applied DNA Sciences, Inc

(Exact Name of Registrant as Specified in Charter)

Nevada (State or Other Jurisdiction of Incorporation) 002-90539 (Commission File Number) 59-2262718 (IRS Employer Identification No.)

25 Health Sciences Drive, Suite 113

Stony Brook, New York 11790

(Address of Principal Executive Offices) (Zip Code)

631-444-6861

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Item 8.01 Other Events.

On April 4, 2007, Applied DNA Sciences, Inc. (the “Company”) issued a press release to announce that the parties to the Sub-License Agreement dated July 29, 2003, by and between the Company, Biowell Technology, Inc. and G.A. Corporate Finance Ltd., have terminated such Sub-License Agreement, and that in connection with such termination all of G.A. Corporate Finance Ltd.’s interests in Applied DNA Sciences Europe Ltd. have been transferred to the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit 99.1 Press release of Applied DNA Sciences, Inc., dated April 4, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Applied DNA Sciences, Inc.
	(Registrant)
	By: /s/ James Hayward
	James Hayward
	Chief Executive Officer
Date: April 4, 2007

Exhibit No.	Description of Exhibit
99.1	Press Release of Applied DNA Sciences, Inc., dated April 4, 2007.

EX-99.1

Applied DNA Sciences Acquires Applied DNA Sciences Europe Ltd.

STONY BROOK, N.Y., April 4, 2007 /Business Wirel/ -- Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN), a DNA security solutions company, today announced that Applied DNA Sciences Europe Ltd., an English private limited company, is now a wholly owned subsidiary of Applied DNA Sciences, Inc. In July 2003, APDN, Biowell Technology, Inc. and G.A. Corporate Finance Ltd. entered into a Sub-License Agreement that provided G.A. Corporate Finance a license to market and sell APDN’s products in the U.K., among other things. G.A. Corporate Finance formed Applied DNA Sciences Europe Ltd. in April 2003 in anticipation of this agreement. On March 30, 2007, the parties terminated this agreement. All rights to market and sell APDN products in the U.K. were returned to APDN, and all of G.A. Corporate Finance’s interests in Applied DNA Sciences Europe Ltd. were transferred to APDN.

“As the company moves forward and continues to establish business relationships with not only U.S., but also European and other companies worldwide, we thought it was important to consolidate rights for our technologies and have direct control of our business in the U.S. and Europe,“ stated Dr. James A. Hayward, CEO of Applied DNA Sciences. “We hope that this strategic move will position the company well for its next phase of growth and will allow APDN to maximize the opportunities we will have in the years ahead.”

About Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc. provides botanical DNA encryption, embedment and authentication solutions that can help protect companies, governments and consumers from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion into physical locations and databases. APDN’s common stock is listed on the Over-The-Counter Bulletin Board under the symbol "APDN".

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-KSB, filed on January 16, 2007 and our subsequent quarterly report on Form 10-QSB. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

SOURCE Applied DNA Sciences, Inc.

-0-03/2x/2007

/CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848/

/FCMN Contact: info@adnas.com /

/Web site: http://www.ADNAS.com /